Status:
ACTIVE_NOT_RECRUITING
NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy
Lead Sponsor:
Peking University People's Hospital
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This is a prospective single-arm clinical study to evaluate the role of NAC after chemotherapy among patients with AML can promote hematopoietic recovery and does not affect the remission rate of the ...
Detailed Description
Hematopoietic recovery after chemotherapy is an important factor affecting the prognosis of acute myeloid leukemia. A previous clinical prospective cohort study showed that NAC could improve the funct...
Eligibility Criteria
Inclusion
- Newly diagnosed AML (except AML-M3)
- Low-, intermediate risk AML (according to 2022 ELN)
- Aged 18-60
- No severe organ injury 1) Creatinine \< 1.5mg/dl 2) Hemobilirubin ≤ 1.5 X ULN 3) AST and ALT ≤ 3.0 X ULN 4) Cardiac ejection index ≥ 50%
- No uncontrolled active infections
- Sign informed consent form, have the ability to comply with study and follow-up procedures
Exclusion
- Hypersensitivity to NAC
- History of bronchial asthma
Key Trial Info
Start Date :
September 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06024031
Start Date
September 10 2023
End Date
September 1 2025
Last Update
November 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yuan Kong
Beijing, Beijing Municipality, China, 100032